Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: A case report

摘要: Bisphosphonates (BP) are inhibitors of bone-resorption and have become the current standard care for preventing skeletal complications associated with bone metastases. Although previous reports also suggested potent antitumor, antiangiogenic immunomodulatory properties BP, there is debate about clinical relevance experimental in vitro vivo findings. We report a renal cell carcinoma case which multiple lung metastases displayed remarkable remission to BP therapy using 30 mg pamidronate once, 4 zoledronate weekly 10 incadronate times 3 months. This first demonstrate that effective non-osseous visceral metastasis as well setting.